Drugs / CS23546
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06245122 | Mar 2024 → Feb 2027 expected | metastatic neoplasm | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS23546 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06245122 ↗ |
| Route | Oral | “Tablets administered orally.” NCT06245122 ↗ |